retatrutide phase 2 trial obesity nejm 2023 triple agonist 🚨Breaking: Retatrutide's first 3 T2D data just dropped. ▸ A1C: −2.0% at 40 weeks ▸ Weight: −36.6 lbs (−16.8%) at 12 mg ▸ No weight loss plateau — curve still descending Triple G Agonists – Retatrutide.

Supplied as a lyophilized powder and sealed against light and moisture shelf-stable, no cold chain required

The evidence for DSIPs effectiveness in chronic insomnia is still inconclusive

The real-world safety profile of tirzepatide: pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database

What Should You Know Before Receiving Glutathione IV Therapy

The effect of glutamine supplementation on athletic performance, body composition, and immune function: A systematic review and a meta-analyis of clinical trials. Clinical Nutrition, June 2019, Arribas-Lpez, Elena et al

Eur J Biochem (1997) 1;246(2):25973